DOCSLIB.ORG

Retinoblastoma High-Dose Chemotherapy with Autologous Stem Cell Rescue in Children with Retinoblastoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Retinoblastoma High-Dose Chemotherapy with Autologous Stem Cell Rescue in Children with Retinoblastoma Bone Marrow Transplantation (2003) 31, 281–284 & 2003 Nature Publishing Group All rights reserved 0268-3369/03 $25.00 www.nature.com/bmt Retinoblastoma High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma B Kremens1, R Wieland1, H Reinhard2, D Neubert5, JD Beck3, T Klingebiel4, N Bornfeld6 and W Havers1 1Department of Pediatrics, University Hospitals of Essen, Germany; 2Department of Pediatrics, University of Homburg/Saar, Germany; 3Department of Pediatrics, University of Erlangen, Germany; 4Department of Pediatrics, University of Frankfurt/Main, Germany; 5Department of Pediatrics of Klinikum Schwerin, Germany; and 6Department of Ophthalmology, University of Essen, Germany Summary: Retinoblastoma is the most common primary tumor of the eye in children.1 Its cure rate reaches 95% (10-year survival Children with metastatic retinoblastoma are considered to probability of 687 patients, German Childhood Cancer have a poor prognosis after conventional chemotherapy. Registry, 2). In most cases, the disease is diagnosed early We used high-dose chemotherapy (HDC)with peripheral and local treatment is instituted promptly. RB remains a hematopoietic stem cell transplantation in such patients in high-risk malignancy, however, under certain circum- an attempt to improve their survival. Four patients with stances, such as involvement of the cut end of the optic bone marrow metastases and one child with extraorbital nerve,3,4 extrascleral spread intothe orbita 5,6 or lymphatic, disease were treated with HDC after achieving complete or hematogenous dissemination.7 Central nervous system remission by enucleation and conventional chemotherapy. disease has a particularly bad prognosis.1,8 Attempts to The child with extraorbital tumor was the only one to control or even cure disseminated retinoblastoma have receive local irradiation. The conditioning regimen followed the strategies used in neuroblastoma, the other included thiotepa (900 mg/m2), etoposide (40 mg/kg) and and more frequent disseminated neuroectodermal malig- carboplatin (1.5 g/m2)in four patients, and BCNU nancy of childhood.9,10 Responses of metastatic retinoblas- (300 mg/m2), cyclophosphamide (6.8 g/m2)and etoposide toma have been shown to respond to cisplatin–etoposide (1.6 g/m2)in one child. Hematologic recovery occurred and cyclophosphamide–doxorubicin,5,11 and to etoposide without delay in all patients. The main toxicities were and carboplatin.12 Since it has been very difficult toconvert diarrhea, mucositis and infectious complications. No toxic such responses into cures,7 the dose–response concept has deaths or any major late toxicities were observed. The been advocated and tried for retinoblastoma as for child treated with the BCNU regimen developed a neuroblastoma, germ-cell tumors or brain tumors. Unlike meningeal relapse 10 months after HDC, which was these diseases, the paucity of patients has prevented a larger partially resected and treated with conventional che- prospective trial to date. motherapy, but not with radiotherapy. He is in complete We report our experience with four children who suffered remission (CR)105 months off treatment. The other from bone marrow metastases of retinoblastoma, re- patients are in CCR for 107, 57, 9 and 8 months after sponded to conventional chemotherapy and received HDC. HDC with thiotepa, etoposide and carboplatin may high-dose consolidation chemotherapy (HDC). A fifth represent a curative option for children with extrabulbar child received the same treatment for extraocular orbital or disseminated retinoblastoma responsive to chemother- disease. apy. It may control occult CNS disease. The necessity to irradiate these children and the curative potential of this strategy for patients with bulky CNS disease remain to be Patients and methods determined. Bone Marrow Transplantation (2003) 31, 281–284. Five children (two girls) received HDC for retinoblastoma doi:10.1038/sj.bmt.1703832 in Germany from 1992 until 2001. In all of them, a Keywords: retinoblastoma; high-dose chemotherapy; unilateral retinoblastoma had primarily been diagnosed at hematopoietic stem cell transplantation the age of 20, 31, 34, 64 and 110 months. In three children, histopathologic risk factors were seen: tumor at the cut end of the optic nerve (patient 2), invasion of the choroid (patients 2, 3) and microscopic extrascleral disease (patient 5). There was no evidence of CNS disease in any of them at Correspondence: Dr B Kremens, Department of Pediatrics, University the time of first diagnosis. The affected eye was enucleated Hospitals of Essen, Hufelandstr. 55, D-45122 Essen, Germany in each case. Patient 5 had documented extrascleral disease, Received 6 June 2002; accepted 23 September 2002 and received additional external irradiation of 48 Gy and High-dose chemotherapy with autologous stem cell B Kremens et al 282 adjuvant chemotherapy according to the Essen Retino- numbers of 450/nl were noted by day 22 (median; range blastoma Protocol (cyclophosphamide, etoposide, carbo- 12–51). The main toxicities included diarrhea and severe platin and vincristine, cf. Bornfeld et al13); nolocal mucositis (WHO grade 3 and 4 in patients 2–5) requiring radiotherapy was given to the other patients. The opiate analgesics in all patients, and nausea and vomiting. characteristics of these patients are summarized in Table 1. All children developed fever and received antibiotics, but Four children (patients 1–4) developed metastatic bone septicemia could not be documented in any of them. marrow involvement 5, 6, 9 and 11 months after eye Transient elevation of liver enzymes was noted in three surgery. Bone scan was negative in all patients except patients. Further acute or late toxicities have not been patient 3, who had lesions in the left temporal bone and in observed to date. the third thoracic vertebra. At this time again, no CNS All patients are alive and well 8–119 months after HDC disease was detectable in them by imaging or CSF cytology. (cf. Table 2). A right frontal meningeal relapse occured in They received multiagent chemotherapy, two children patient 1 10 months after HDC. After partial metastasect- according to the Neuroblastoma Protocol NB 90, Protocol omy and conventional chemotherapy according to the of the German Society of Pediatric Oncology/Hematology, Essen Retinoblastoma Protocol13 plus multiple intrathecal (including cisplatin, etoposide, vindesine, vincristine, of methotrexate injections, this boy has been in second CR DTIC, ifosfamide and doxorubicin), and two children for 105 months (no radiotherapy). according to the Essen Retinoblastoma Protocol.13 In all five children, peripheral blood stem cells (PBSC) were mobilized using filgrastim 5 mg/kg/day subcutaneously after Discussion one of the chemotherapy blocks, in patient 2 after treatment with 4 g/m2 of cyclophosphamide. The PBSC For many years, retinoblastoma confined to the eye has were cryopreserved; in patients 3 and 4, a CD34+ selection been a curable disease with local therapy such as was performed beforehand. Informed consent was obtained enucleation, external beam irradiation, brachytherapy, from the parents of each patient. cryotherapy or laser coagulation.1 In contrast, systemic All patients were in complete remission (CR) at the time disease is difficult to cure, although it usually responds to of HDC (cf. Table 2). chemotherapy.5–7 As in other malignancies of similar During the period of HDC, supportive care was given prognosis, high dose intensification of chemotherapy has according to local standards, including barrier nursing, been tried for retinoblastoma. Two case reports of patients selective oral decontamination, oral antifungal treatment, with bone marrow metastases who received HDC in pneumocystis carinii prophylaxis with trimethoprim/sulfa- complete remission and survived in continuous remission methoxazole before day 0 and after hematopoietic recov- 13 and 17 months thereafter gave a first hint to the ery, and parenteral nutritional support as necessary. As possiblility of cure in metastatic retinoblastoma.14,15 Later, consolidation therapy, patient 1 received BCNU 300 mg/ the group of the Institut Curie in Paris published their m2, cyclophosphamide 6.8 g/m2 and etoposide 1.6 g/m2. results after treating 25 high-risk patients with retinoblas- Patients 2–5 received HDC treatment with thiotepa 900 mg/ toma, with HDC consisting of carboplatin, etoposide and m2, etoposide 40 mg/kg and carboplatin 1.5 g/m2 (cf. cyclophosphamide (CARBOPEC), followed by autologous Table 3). PBSC containing 1.7–21.0 Â 106 CD34+ cells/ bone marrow rescue. Among eight children with bone kg were thawed and infused on day 0. Concomitantly, marrow and bone metastases, five survived between 11 and treatment with filgrastim at a dose of 5 mg/kg/day was 70 months disease free, while three patients relapsed in the initiated and continued until stable neutrophil engraftment CNS and died.8 Among all 25 patients, a total of seven was reached. suffered from recurrence after this HDC, six of these seven within the CNS. The authors conclude that CNS disease cannot be cured with the CARBOPEC regimen.8 Results CNS involvement is well known to confer a very poor prognosis. Aggressive chemotherapy regimens including Prompt reconstitution of bone marrow occured in all CCNU, intrathecal therapy and cranial irradiation have patients. Neutrophil counts of 40.5/nl were reached on resulted in considerable toxicity, but have not yielded an day 10 (median; range 8–22). Rising unsupported platelet applicable
Load more

Recommended publications
  • Pearls and Forget-Me-Nots in the Management of Retinoblastoma
    POSTERIOR SEGMENT ONCOLOGY FEATURE STORY Pearls and Forget-Me-Nots in the Management of Retinoblastoma Retinoblastoma represents approximately 4% of all pediatric malignancies and is the most common intraocular malignancy in children. BY CAROL L. SHIELDS, MD he management of retinoblastoma has gradu- ular malignancy in children.1-3 It is estimated that 250 to ally evolved over the years from enucleation to 300 new cases of retinoblastoma are diagnosed in the radiotherapy to current techniques of United States each year, and 5,000 cases are found world- chemotherapy. Eyes with massive retinoblas- Ttoma filling the globe are still managed with enucleation, TABLE 1. INTERNATIONAL CLASSIFICATION OF whereas those with small, medium, or even large tumors RETINOBLASTOMA (ICRB) can be managed with chemoreduction followed by Group Quick Reference Specific Features tumor consolidation with thermotherapy or cryotherapy. A Small tumor Rb <3 mm* Despite multiple or large tumors, visual acuity can reach B Larger tumor Rb >3 mm* or ≥20/40 in many cases, particularly in eyes with extrafoveal retinopathy, and facial deformities that have Macula Macular Rb location been found following external beam radiotherapy are not (<3 mm to foveola) anticipated following chemoreduction. Recurrence from Juxtapapillary Juxtapapillary Rb location subretinal and vitreous seeds can be problematic. Long- (<1.5 mm to disc) term follow-up for second cancers is advised. Subretinal fluid Rb with subretinal fluid Most of us can only remember a few interesting points C Focal seeds Rb with: from a lecture, even if was delivered by an outstanding, Subretinal seeds <3 mm from Rb colorful speaker. Likewise, we generally retain only a small and/or percentage of the information that we read, even if writ- Vitreous seeds <3 mm ten by the most descriptive or lucent author.
    [Show full text]
  • Metabolic Profiling of the Three Neural Derived Embryonal Pediatric Tumors
    Metabolic profiling of the three neural derived embryonal pediatric tumors retinoblastoma, neuroblastoma and medulloblastoma, identifies distinct metabolic profiles Kohe, Sarah; Bennett, Christopher; Gill, Simrandip; Wilson, Martin; McConville, Carmel; Peet, Andrew DOI: 10.18632/oncotarget.24168 License: Creative Commons: Attribution (CC BY) Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Kohe, SE, Bennett, CD, Gill, SK, Wilson, M, McConville, C & Peet, AC 2018, 'Metabolic profiling of the three neural derived embryonal pediatric tumors retinoblastoma, neuroblastoma and medulloblastoma, identifies distinct metabolic profiles', OncoTarget, vol. 9, no. 13, pp. 11336-11351. https://doi.org/10.18632/oncotarget.24168 Link to publication on Research at Birmingham portal General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain. Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
    [Show full text]
  • Retinoblastoma
    A Parent’s Guide to Understanding Retinoblastoma 1 Acknowledgements This book is dedicated to the thousands of children and families who have lived through retinoblastoma and to the physicians, nurses, technical staf and members of our retinoblastoma team in New York. David Abramson, MD We thank the individuals and foundations Chief Ophthalmic Oncology who have generously supported our research, teaching, and other eforts over the years. We especially thank: Charles A. Frueauf Foundation Rose M. Badgeley Charitable Trust Leo Rosner Foundation, Inc. Invest 4 Children Perry’s Promise Fund Jasmine H. Francis, MD The 7th District Association of Masonic Lodges Ophthalmic Oncologist in Manhattan Table of Contents What is Retinoblastoma? ..........................................................................................................3 Structure & Function of the Eye ...........................................................................................4 Signs & Symptoms .......................................................................................................................6 Genetics ..........................................................................................................................................7 Genetic Testing .............................................................................................................................8 Examination Schedule for Patients with a Family History ........................................ 10 Retinoblastoma Facts ................................................................................................................11
    [Show full text]
  • Neurofibromatosis Type 1 and Type 2 Associated Tumours: Current Trends in Diagnosis and Management with a Focus on Novel Medical Therapies
    Neurofibromatosis Type 1 and Type 2 Associated Tumours: Current trends in Diagnosis and Management with a focus on Novel Medical Therapies Simone Lisa Ardern-Holmes MBChB, MSc, FRACP A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Faculty of Health Sciences, The University of Sydney February 2018 1 STATEMENT OF ORIGINALITY This is to certify that this submission is my own work and that, to the best of my knowledge, it contains no material previously published or written by another person, or material which to a substantial extent has been accepted for the award of any other degree or diploma of the university or other institute of higher learning, except where due acknowledgement has been made in the text. Simone L. Ardern-Holmes 2 SUMMARY Neurofibromatosis type 1 (NF1) and Neurofibromatosis type 2 (NF2) are distinct single gene disorders, which share a predisposition to formation of benign nervous system tumours due to loss of tumour suppressor function. Since identification of the genes encoding NF1 and NF2 in the early 1990s, significant progress has been made in understanding the biological processes and molecular pathways underlying tumour formation. As a result, identifying safe and effective medical approaches to treating NF1 and NF2-associated tumours has become a focus of clinical research and patient care in recent years. This thesis presents a comprehensive discussion of the complications of NF1 and NF2 and approaches to treatment, with a focus on key tumours in each condition. The significant functional impact of these disorders in children and young adults is illustrated, demonstrating the need for coordinated care from experienced multidisciplinary teams.
    [Show full text]
  • RETINOBLASTOMA Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines
    RETINOBLASTOMA Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines RETINOBLASTOMA Executive Summary Retinoblastoma is the most frequent neoplasm of the eye in childhood, and represents 3% of all childhood malignancies. It is a cancer of the very young; two-thirds are diagnosed before 2 years of age, and 95% before 5 years. For these reasons, therapeutic approaches need to consider not only the cure of the disease but also the need to preserve vision with minimal long-term side effects. The average age-adjusted incidence rate of retinoblastoma in the United States and Europe is 2-5/106 children (approximately 1 in 14,000 – 18,000 live births). However, the incidence of retinoblastoma is not distributed equally around the world. It appears to be higher (6-10/106 children) in Africa, India, and among children of Native American descent in the North American continent. 1 Whether these geographical variations are due to ethnic or socioeconomic factors is not well known. However, the fact that even in industrialized countries an increased incidence of retinoblastoma is associated with poverty and low levels of maternal education, suggests a role for the environment. 2,3 Retinoblastoma presents in two distinct clinical forms: (1) A bilateral or multifocal, heritable form (25% of all cases), characterized by the presence of germ-line mutations of the RB1 gene; and (2) a unilateral or unifocal form (75% of all cases), 90% of which are non-hereditary. The most common presenting sign of retinoblastoma is leukocoria, and some patients may also present with strabismus.
    [Show full text]
  • Clinical and Genetic Patterns Ofneurofibromatosis 1 and 2
    662 BritishJournalofOphthalmology 1993; 77: 662-672 PERSPECTIVE Br J Ophthalmol: first published as 10.1136/bjo.77.10.662 on 1 October 1993. Downloaded from Clinical and genetic patterns of neurofibromatosis 1 and 2 Nicola K Ragge General introduction to the neurofibromatoses Neurofibromatosis type 1 The diseases traditionally known as neurofibromatosis have now been formally separated into two types: neurofibromato- CLINICAL ASPECTS sis type 1 or NFl (the type described by von Recklinghausen) Neurofibromatosis type 1 (NFI) is the commonest form of and neurofibromatosis type 2 or NF2 (a much rarer form).' It neurofibromatosis and has a frequency of about 1 in 3000 to is now recognised that although they have overlapping 1 in 3500.192° Although the gene is almost 100% penetrant, features, including an inherited propensity to neurofibromas the disease itselfhas extremely variable expressivity.20 About and tumours of the central nervous system, they are indeed 50% ofindex cases and 30% ofall NFl cases are considered to separate diseases and map to different chromosomes - 17 for be new mutations. The high mutation rate may be due in part NFl and 22 for NF2. Furthermore, developmental abnor- to the large size of the gene and its transcript, or possibly to malities such as hamartomas occur in both types of neuro- the presence of sequences within the gene highly susceptible fibromatosis, illustrating a need to define the role of the to mutation. normal NF genes in development. There may also be further forms of neurofibromatosis, including NF3, NF4, multiple meningiomatosis, and spinal Clinicalfeatures schwannomatosis, that do not fit precisely into current Particular clinical features are critical for establishing the diagnostic classifications.
    [Show full text]
  • Molecular Genetics of Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma
    Neurosurg Focus 19 (5):E3, 2005 Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma MEI HUA LI, PH.D., ERIC BOUFFET, M.D., CYNTHIA E. HAWKINS, M.D., PH.D., JEREMY A. SQUIRE, PH.D., AND ANNIE HUANG, M.D., PH.D. Arthur and Sonia Labatt Brain Tumor Research Centre, Cancer Research Program, Division of Hematology and Oncology, and Department of Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto; Ontario Cancer Institute, Toronto; and Department of Pathobiology and Laboratory Medicine, University of Toronto, Ontario, Canada The supratentorial primitive neuroectodermal tumors (PNETs) are a group of highly malignant lesions primarily affecting young children. Although these tumors are histologically indistinguishable from infratentorial medulloblas- toma, they often respond poorly to medulloblastoma-specific therapy. Indeed, existing molecular genetic studies indi- cate that supratentorial PNETs have transcriptional and cytogenetic profiles that are different from those of medullo- blastomas, thus pointing to unique biological derivation for the supratentorial PNET. Due to the rarity of these tumors and disagreement about their histopathological diagnoses, very little is known about the molecular characteristics of the supratentorial PNET. Clearly, future concerted efforts to characterize the molecular features of these rare tumors will be necessary for development of more effective supratentorial PNET treatment protocols and appropriate disease models. In this article the authors review existing molecular genetic data derived from human and mouse studies, with the aim of providing some insight into the putative histogenesis of these rare tumors and the underlying transforming pathways that drive their development. Studies of the related but distinct pineoblastoma PNET are also reviewed. KEY WORDS • supratentorial primitive neuroectodermal tumor • pineoblastoma • molecular genetics OVERVIEW PNETs have molecular features that are unique from those of The supratentorial PNET and pineoblastoma are high- medulloblastoma.
    [Show full text]
  • Pineal Malignant Neoplasm in Association with Hereditary Retinoblastoma
    Br J Ophthalmol: first published as 10.1136/bjo.69.10.749 on 1 October 1985. Downloaded from British Journal of Ophthalmology, 1985, 69, 749-753 Pineal malignant neoplasm in association with hereditary retinoblastoma CLARE STANNARD,' B K KNIGHT,2 AND R SEALY' From the Department of'Radiotherapy and 'Pathology, Groote Schuur Hospital and University ofCape Town, South Africa SUMMARY A patient with unilateral hereditary retinoblastoma who was successfully treated at the age of 7 weeks developed a tumour in the pineal region two and a half years later. The initial response to radiation treatment of the latter lesion was not maintained. Subsequent necropsy findings are described. Clinically and pathologically this case represents an example of the recently described trilateral retinoblastoma. The response to treatment after early recognition was disappointing. Several reports have described the occurrence of physical abnormalities. A diagnosis of retino- second malignancies in patients treated for bilateral blastoma was made. copyright. retinoblastoma. '-' One report' included three The patient was treated with dibromodulcitol patients with intracranial malignancies, of which one 3*5 mg/kg body weight and procarbazine 75 mg/m2; was clinically a pinealoma. In 1977, Jakobiec et al.' both drugs were given daily for 33 days. EUA after 11 described two neuroblastic intracranial tumours in days showed that the tumour had regressed from the patients with retinoblastoma, one of which was a optic disc. After a further 10 days radiation treatment pineal tumour. More recently the association of a was started with 250kV x-rays, 3 5 mm copper half pineal tumour with bilateral retinoblastoma has been value layer, and a tumour dose of 3095 cGy given.
    [Show full text]
  • An Unusual ENT Presentation of Retinoblastoma:10.5005/Jp-Journals-10013-1291 a Diagnostic Dilemma Coase Rep Rt
    AIJCR An Unusual ENT Presentation of Retinoblastoma:10.5005/jp-journals-10013-1291 A Diagnostic Dilemma COASE REP RT An Unusual ENT Presentation of Retinoblastoma: A Diagnostic Dilemma 1Tamoghna Jana, 2Moushumi Sengupta, 3Saumik Das, 4Asok K Saha, 5Subhasis Saha ABSTRACT histopathological slides and immunohistochemical study Retinoblastoma is the most common intraocular tumor of are therefore an essential tool to rule out any diagnostic childhood. These tumors, though they respond to treatment, dilemma. are prone to develop secondary malignancy, recurrence, and metastasis, which may present as sinonasal mass. We are CASE REPORT presenting a rare case of metastatic retinoblastoma of sinonasal region in a 3-year-old male child. The mode of presentation A 3-year-old male child presented to the ear, nose, and and management of the case is presented along with a review throat outpatient department of the Medical College and of the literature. Hospital in April 2013 with a painful, tender swelling of Keywords: Metastatic, Retinoblastoma, Sinonasal. the right side of face, which developed 3 weeks earlier and How to cite this article: Jana T, Sengupta M, Das S, Saha was rapidly increasing in size. The patient had a history AK, Saha S. An Unusual ENT Presentation of Retinoblastoma: of enucleation of the left eye in June 2012. Histopathologi- A Diagnostic Dilemma. Clin Rhinol An Int J 2016;9(3):149-152. cal examination confirmed it as primary retinoblastoma Source of support: Nil with involvement of the choroid and sclera for which the patient received postoperative radiotherapy by 21 Conflict of interest: None fraction, which was completed in September 2012.
    [Show full text]
  • Retinoblastoma Or Neuroblastoma: an Imaging Polemic Issues
    International Journal of Research in Medical Sciences Giri WW et al. Int J Res Med Sci. 2020 Feb;8(2):771-776 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20200273 Case Report Retinoblastoma or Neuroblastoma: an imaging polemic issues Winda W. Giri1*, Yuli Anandasari1, Ni Nyoman Margiani1, Dwija Putra Ayusta1, Ketut Ariawati2, Sri Mahendra Dewi3 1Department of Radiology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia 2Department of Pediatric Hemato-Oncology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia 3Department of Histopathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia Received: 09 December 2019 Revised: 15 December 2019 Accepted: 03 January 2020 *Correspondence: Dr. Winda W. Giri, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Both retinoblastoma and neuroblastoma are common childhood malignancy, which classified as malignant round cell tumors, but have different diagnostic, therapeutic, prognostic criteria and metastases pattern. A case was evaluated with an imaging examination resembled neuroblastoma metastatic process but was diagnosed as retinoblastoma.
    [Show full text]
  • The Pathogenesis of Neurofibromatosis 1 and Neurofibromatosis 2
    Chapter_3_p23-42 10/11/04 5:55 PM Page 23 3 The Pathogenesis of Neurofibromatosis 1 and Neurofibromatosis 2 The neurofibromatoses are genetic disorders. NF1 and NF2 are each caused by a mutation in a known specific gene. The quest to understand how these disorders originate and progress (their pathogenesis) received a significant boost when researchers identified the causative genes. The leading theories about the pathogenesis of NF1 and NF2 are discussed in this chapter. Because the search for the biological cause of schwanno- matosis was still underway when this book went to press, less is known about its pathogenesis (see Chapter 12). N A Search for Answers In 1990, two groups of scientists working separately located the NF1 gene on chromosome 17 and characterized its protein product, neurofi- bromin.1–3 In 1993, another two teams working separately identified the NF2 gene on chromosome 22; one named its protein “merlin”4 and the other “schwannomin.”5 Once the genes were identified, work could begin on better understanding how mutations lead to tumor formation and other manifestations. The search for answers, however, has been daunting. There is proba- bly no single answer to the question, What causes NF1 and NF2? Just as 23 Chapter_3_p23-42 10/11/04 5:55 PM Page 24 24 Neurofibromatosis these disorders cause various types of manifestations, so too there appear to be multiple molecular mechanisms at work. When trying to understand the pathogenesis of a disorder, scientists may combine two techniques that approach the question from different directions. The traditional phenotypical approaches analyze the physical manifestations of the disorders, such as what cells are involved and how they function, and then work backward to determine what gene might cause these abnormalities.
    [Show full text]
  • Retinoblastoma Tumor Collection
    2/2/13 /Retinoblastoma/Chapter contents Chapter 42 – Retinoblastoma Brenda L Gallie, Mandeep S Sagoo, M Ashwin Reddy Chapter contents PATHOGENESIS OF RETINOBLASTOMA PRESENTATION DIAGNOSIS TREATMENT EXTRAOCULAR RETINOBLASTOMA PROGNOSIS LONG­TERM FOLLOW­UP LIFE­LONG IMPLICATIONS OF RETINOBLASTOMA REFERENCES Retinoblastoma is an uncommon malignant ocular tumor of childhood, occurring in 1 : 18 000 live births.[1] Late diagnosis globally results in up to 70% mortality; where optimal therapy is accessible, more than 95% of children are cured. An integrated team approach of clinical specialists (ophthalmologists, pediatric oncologists and radiotherapists, nurses, geneticists) with imaging specialists, child life (play) specialists, parents, and others is an effective way to manage retinoblastoma. National guidelines can bring the whole health team up to developed standards and set the stage for audits, studies, and clinical trials to continuously evolve better care and outcomes.[2] The tumor(s) arises from embryonic retinal cells so the majority of cases occur under the age of 4 years. Primary treatments include enucleation and chemotherapy with laser and cryotherapy. Patients with a constitutional mutation of the RB1 tumor suppressor gene are at increased life­long risk of developing other cancers, which is increased with exposure to radiation (Figs 42.1 and 42.2).[3,4] Therefore, radiation is no longer a primary therapy to save an eye, and screening for extraocular and trilateral retinoblastoma is performed with MRI and ultrasound, not CT scan. The study of retinoblastoma has been seminal in the understanding of cancer in general. Studies of retinoblastoma have revealed that hereditary and non­hereditary tumors are initiated by the loss of both alleles of the tumor suppressor gene, RB1.[5,6] The existence of specific genes that act to suppress cancer was predicted from clinical studies of retinoblastoma.[7,8] The RB1 gene was the first tumor suppressor gene to be cloned,[5] and has been found to have a critical role in many types of cancer.
    [Show full text]